Sale strategies of pharmaceutical companies in a "pharmerging" country: The problems will not improve if the gaps remain

Health Policy

Volumn 106, Issue 3, 2012, Pages 225-232

  Civaner, Murat ^a  

^a ULUDAG UNIVERSITY   (Turkey)

Author keywords

Drug industry; Marketing; Medical ethics; Physicians; Professionalism

Indexed keywords

ARTICLE; DRUG INDUSTRY; DRUG MARKETING; EMPLOYEE; HEALTH CARE POLICY; HEALTH ECONOMICS; INTERVIEW; PHARMACIST; PHYSICIAN; QUALITATIVE RESEARCH;

DRUG INDUSTRY; ETHICS, MEDICAL; HUMANS; MARKETING; QUALITATIVE RESEARCH; TURKEY;

EID: 84863780162     PISSN: 01688510     EISSN: 18726054     Source Type: Journal    
DOI: 10.1016/j.healthpol.2012.05.006     Document Type: Article

References (56)

1. IMS. IMS health lowers 2009 global pharmaceutical market forecast to 2.5-3.5 percent growth, 2009. http://getir.net/za42.
2. Public Citizen. 2002 Drug industry profits: hefty pharmaceutical company margins dwarf other industries. Washington: Public Citizen's Congress Watch, 2003:6.
3. Kaiser Foundation. Trends in promotional spending for prescription drugs, 1996-2007, 2009. http://facts.kff.org/chart.aspx?ch=225.
4. Abbasi K., Smith R. No more free lunches. BMJ 2003, 326:1155-1156.
5. Burton B., Rowell A. Unhealthy spin. BMJ 2003, 326:1205-1207.
6. Giannakakis I.A., Ioannidis J.P. Arabian nights-1001 tales of how pharmaceutical companies cater to the material needs of doctors: case report. BMJ 2000, 321:1563-1564.
7. Gibson E., Baylis F., Lewis S. Dances with the pharmaceutical industry. Canadian Medical Association Journal 2002, 166:448-450.
8. Kjaergard L.L., ls-Nielsen B. Association between competing interests and authors' conclusions: epidemiological study of randomised clinical trials published in the BMJ. BMJ 2002, 325:249.
9. Koch K. Schering uses German medical association to promote HRT. BMJ 2003, 326. 1161-116a.
10. Lenzer J. FDA's counsel accused of being too close to drug industry. BMJ 2004, 329:189.
11. Liberati A., Magrini N. Information from drug companies and opinion leaders. BMJ 2003, 326:1156-1157.
12. Rao J.N., Cassia L.J. Ethics of undisclosed payments to doctors recruiting patients in clinical trials. BMJ 2002, 325:36-37.
13. Sheldon T. Drug company fined for excessive hospitality. BMJ 2001, 322:382.
14. Smith R. Medical journals and pharmaceutical companies: uneasy bedfellows. BMJ 2003, 326:1202-1205.
15. Tonks A. Authors of guidelines have strong links with drugs industry. BMJ 2002, 324:383a.
16. Lexchin J. Interactions between physicians and the pharmaceutical industry: what does the literature say?. CMAJ: Canadian Medical Association Journal 1993, 149:1401-1407.
17. Mansfield P.R., Lexchin J., Wen L.S., Grandori L., McCoy C.P., Hoffman J.R., et al. Educating health professionals about drug and device promotion: advocates' recommendations. PLoS Medicine 2006, 3:e451.
18. Norris P., Herxheimer A., Lexchin J., Mansfield P. Drug promotion: what we know, what we yet to learn 2005, WHO and HAI, Geneva.
19. Wazana A. Physicians and the pharmaceutical industry: is a gift ever just a gift?. JAMA: The Journal of the American Medical Association 2000, 283:373-380.
20. IMF. World Economic Outlook Database, Nominal GDP list of countries for the year 2010, 2011. http://www.imf.org/external/pubs/ft/weo/2011/02/weodata/index.aspx.
21. World Bank. World Bank - Turkey partnership: country program snapshot, 2011. http://siteresources.worldbank.org/ECAEXT/Resources/Turkey_Snapshot.pdf.
22. OECD. How's life? 2011. doi:10.1787/9789264121164-en.
23. UNDP. International human development indicators. Regional and national trends in the human development index 1980-2011, 2011. http://hdr.undp.org/en/data/trends.
24. World Bank. Health transformation and social security reform project, 2011. http://getir.net/zaah.
25. IMS. Emerging markets account for more than a third of global pharmaceutical market growth, 2009. http://getir.net/0kb.
26. PriceWaterhouseCoopers. Pharma 2020: The vision. Which path will you take? 2007. http://www.pwc.com/tr_TR/TR/publications/industrial/pharma/published/PHARMA_2020_FINAL.pdf.
27. Turkiye Ilac Sanayii Dernegi. Dunya ilac pazari, 2010, 2011. http://www.tisd.org.tr/DunyaPazar.asp.
28. Deloitte Turkey. Turkiye'de saglik ekonomisi ve ilac sanayii. Istanbul; 2011, p. 11.
29. Pharmaceutical manufacturers association of Turkey. Pharmaceutical market and consumption, 2011. http://www.ieis.org.tr/asp-pages/index.asp%3Fsayfa=215%26menuk=12.
30. OECD. OECD health data - frequently requested data, 2009. http://www.oecd.org/document/16/0,3343,en_2649_34631_2085200_1_1_1_1,00.html.
31. Seidman I. Interviewing as qualitative research 2006, Teachers College Press, New York.
32. Baird P. Getting it right: industry sponsorship and medical research. Canadian Medical Association Journal 2003, 168:1267-1269.
33. Bodenheimer T, Collins R. Telling the truth: what drug companies don't want you to know, 2006. http://www.cspinet.org/integrity/tell_truth.html.
34. Davis D.A. CME and the pharmaceutical industry: two worlds, three views, four steps. Canadian Medical Association Journal 2004, 171:149-150.
35. Lexchin J. Doctors and detailers: therapeutic education or pharmaceutical promotion?. International Journal of Health Services 1989, 19:663-679.
36. Marwick C. Journal "should have revealed scientist's connection to company" BMJ 2002, 324:70.
37. Melander H., hlqvist-Rastad J., Meijer G., Beermann B. Evidence b(i)ased medicine-selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications. BMJ 2003, 326:1171-1173.
38. Moynihan R. Who pays for the pizza? Redefining the relationships between doctors and drug companies. 2: Disentanglement. BMJ 2003, 326:1193-1196.
39. Sheldon T. GPs warned on accepting hospitality from drug companies. BMJ 2001, 322:194.
40. Varley C.K., Jibson M.D., McCarthy M., Benjamin S. A survey of the interactions between psychiatry residency programs and the pharmaceutical industry. Acadmey of Psychiatry 2005, 29:40-46.
41. Wager E. How to dance with porcupines: rules and guidelines on doctors' relations with drug companies. BMJ 2003, 326:1196-1198.
42. Elliott C. Pharma goes to the laundry: public relations and the business of medical education. Hastings Center Report 2004, 34:18-23.
43. Gottlieb S. Medical societies accused of being beholden to the drugs industry. BMJ 1999, 319:1321.
44. Herxheimer A. Relationships between the pharmaceutical industry and patients' organisations. BMJ 2003, 326:1208-1210.
45. Mintzes B. For and against: direct to consumer advertising is medicalising normal human experience: For. BMJ 2002, 324:908-909.
46. Moynihan R. Drug firms hype disease as sales ploy, industry chief claims. BMJ 2002, 324:867.
47. Moynihan R. Drug company sponsorship of education could be replaced at a fraction of its cost. BMJ 2003, 326:1163.
48. Singh D. Drug companies advised to publish unfavourable trial results. BMJ 2003, 326. 1163-116a.
49. Sismondo S. Pharmaceutical Maneuvers. Social Studies of Science 2004, 34:149-159.
50. Wagena E.J., Knipschild P. Do drug firms hoodwink medical journals? Or is something wrong with the contribution and integrity of declared authors?. Journal of Medical Ethics 2005, 31:307.
51. Caudill T.S., Johnson M.S., Rich E.C., McKinney W.P. Physicians, pharmaceutical sales representatives, and the cost of prescribing. Archives of Family Medicine 1996, 5:201-206.
52. Dogramatzis D. Pharmaceutical marketing. A practical guide 2002, Taylor & Francis, Florida, p. 70.
53. Kotler P., Keller K.L. Marketing management 2006, Pearson Education, New Jersey, p. 144.
54. Charatan F. Doctors say they are not influenced by drug companies' promotions. BMJ 2001, 322:1081.
55. Steinman M.A., Shlipak M.G., McPhee S.J. Of principles and pens: attitudes and practices of medicine housestaff toward pharmaceutical industry promotions. American Journal of Medicine 2001, 110:551-557.
56. WHO. Drug promotion database, 2009. http://www.drugpromo.info/.